CV Lattes
GoogleMyCitations
ResearcherID
Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. Escola Paulista de Medicina (EPM) (Institutional affiliation for the last research proposal) Birthplace: Brazil
In 1988, I graduated in Medicine at Escola Paulista de Medicina and, in the years following the Medical Residency in Hematology and Hemotherapy, I obtained Masters? and PhD degrees at Federal University of São Paulo (1993 and 1995, respectively), Brazil. I developed my postdoctoral studies in the area of Molecular Pathology in lymphoproliferative diseases at Memorial Sloan-Kettering Cancer Center, New York, USA (1998-1999). Currently, I am Full Professor at Clinical and Experimental Oncology Department of UNIFESP, where I have been developing interdisciplinary studies - with the collaboration of basic and clinical researchers in Brazil and abroad - in hematological cancers (biomarkers and therapeutic targets), with financial support of FAPESP, CAPES and CNPq in the last 20 years. Currently, I am an advisor for AGiTS (Agência de Inovação Tecnológica e Social, UNIFESP) and for Brazilian financial agencies FAPESP, CNPq , CAPES, Department of Science and Technology of the Brazilian Ministry of Health, FWO (Belgium) and LLR (Leukemia Lymphoma Research), and reviewer of 40 international journals. In February 2020, I completed 40 sponsorships (scientific initiation, master's, doctorate and postdoctoral supervision) and 91 papers published in peer-reviewed journals. https://scholar.google.com.br/citations?user=IaY4gTgAAAAJ&hl=en&oi=ao (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| @ |
Bone marrow neoplasias are aggressive disorders with low healing potential. As the incidence of cancer increases with age, a growing number of older individuals are receiving therapy for cancer and frequently in intensive modalities. As these older patients tend to present comorbidities, treatment decisions can often become difficult due to their fragile physical state which may affect th…
The main objective of this proposal is the development of studies that aggressively seek possible biomarkers and therapeutic targets four frequent B-cell lymphoproliferative disorders: multiple myeloma (MM), diffuse large B-cell lymphomas (DLBCL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The subproject 1 aims at identifying mutations JAK/STAT pathway genes and po…
The aims of this study are: 1) to correlate gene expression profiles with clinical staging at diagnosis, cytogenetic abnormalities, cell surface antigens and histology of bone marrow in MM patients; 2) to identify changes in gene expression profiles in MM patients induced by treatment with thalidomide; 3) to correlate eventual heterogeneity of gene expression at diagnosis with therapeutic…
Chronic myeloid leukemia is a myeloproliferative neoplasia which affects middle-aged people. Its physiopathology is related to the existence of a reciprocal translocation between chromosomes 9 and 22, creating a marker chromosome, the Philadelphia (Ph1), and the oncogene BCR-ABL. This gene has tyrosine kinase activity and the treatment is made with inhibitors of the enzime (TKi). Although…
Multiple myeloma (MM) is a malignant hematologic cancer characterized by infiltration of plasma tumor cells into the bone marrow (BM), synthesis and secretion of clonal immunoglobulins and tissue damage such as bone lesions, hypercalcemia, anemia and renal failure. Despite progress in treatment, the MM remains incurable due to high rate of relapse. The presence of cancer stem cells (CSCs)…
Multiple Myeloma (MM) is the second most prevalent hematological neoplasia in the United States. It is characterized by infiltration of tumor plasma cells in the bone marrow, synthesis of monoclonal immunoglobulins and tissue damages, such as osteolytic lesions. Despite of the progress achieved in the last decades regarding the frontline treatment for MM, this malignant neoplasia remains …
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing research grants |
| 7 / 2 | Completed research grants |
| 13 / 11 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 22 / 15 | All research grants and scholarships |
| Associated processes | |
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
| Publications | 17 |
| Citations | 168 |
| Cit./Article | 9.9 |
| Data from Web of Science | |
BARBOSA, REBECCA S. S.; DANTONIO, PAOLA M.; GUIMARAES, TAIS; DE OLIVEIRA, MARIANA B.; FOOK ALVES, VERUSKA L.; SANDES, ALEX FREIRE; FERNANDO, RODRIGO CARLINI; COLLEONI, GISELE W. B.. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. Biochemical and Biophysical Research Communications, v. 519, n. 3, p. 597-604, NOV 12 2019. Web of Science Citations: 0. (10/17668-6, 17/21801-2, 15/23983-5, 17/17101-5)
ANDRADE, VALERIA C. C.; VETTORE, ANDRE L.; REGIS SILVA, MARIA REGINA; FELIX, ROBERTA S.; ALMEIDA, MANUELLA S. S.; DE CARVALHO, FABRICIO; ZAGO, MARCO ANTONIO; CABALLERO, OTAVIA L.; SIMPSON, ANDREW J.; COLLEONI, GISELE W. B.. Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. Experimental Hematology, v. 37, n. 4, p. 446-449, APR 2009. Web of Science Citations: 11.
SAMPAIO ALMEIDA, MANUELLA S.; VETTORE, ANDRE L.; YAMAMOTO, MIHOKO; CHAUFFAILLE, MARIA DE LOURDES L. F.; ZAGO, MARCO ANTONIO; COLLEONI, GISELE W. B.. Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. HISTOLOGY AND HISTOPATHOLOGY, v. 24, n. 8, p. 991-997, AUG 2009. Web of Science Citations: 8.
DE CARVALHO, FABRICIO; COLLEONI, GISELE W. B.; SAMPAIO ALMEIDA, MANUELLA S.; CARVALHO, ANDRE L.; VETTORE, ANDRE L.. TGF beta R2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. International Journal of Cancer, v. 125, n. 8, p. 1985-1991, OCT 15 2009. Web of Science Citations: 37.
FELIX, ROBERTA S.; COLLEONI, GISELE W. B.; CABALLERO, OTAVIA L.; YAMAMOTO, MIHOKO; ALMEIDA, MANUELLA S. S.; ANDRADE, VALERIA C. C.; CHAUFFAILLE, MARIA DE LOURDES L. F.; DA SILVA, JR., WILSON A.; BEGNAMI, MARIA DIRLEI; SOARES, FERNANDO AUGUSTO; et al. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Cancer Letters, v. 278, n. 1, p. 41-48, JUN 8 2009. Web of Science Citations: 29.
ANDRADE, VALERIA C. C.; VETTORE, ANDRE L.; PANEPUCCI, RODRIGO A.; ALMEIDA, MANUELLA S. S.; YAMAMOTO, MIHOKO; DE CARVALHO, FABRICIO; CABALLERO, OTAVIA L.; ZAGO, MARCO ANTONIO; COLLEONI, GISELE W. B.. Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. Leukemia & Lymphoma, v. 51, n. 8, p. 1543-1549, AUG 2010. Web of Science Citations: 3.
DE OLIVEIRA, MARIANA B.; FOOK-ALVES, VERUSKA L.; EUGENIO, ANGELA I. P.; FERNANDO, RODRIGO C.; SANSON, LUIZ FELIPE G.; DE CARVALHO, MARIANA F.; BRAGA, WALTER M. T.; DAVIES, FAITH E.; COLLEONI, GISELE W. B.. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. Cancer Letters, v. 403, p. 206-215, SEP 10 2017. Web of Science Citations: 9. (10/17668-6)
TOBIAS BRAGA, WALTER MOISES; DA SILVA, BRUNA RAPHAELI; DE CARVALHO, ANA CAROLINA; MAEKAWA, YUMI H.; BORTOLUZZO, ADRIANA BRUSCATO; RIZZATTI, EDGAR GIL; ATANACKOVIC, DJORDJE; BRAGA COLLEONI, GISELE WALLY. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. CANCER IMMUNOLOGY IMMUNOTHERAPY, v. 63, n. 11, p. 1189-1197, NOV 2014. Web of Science Citations: 29. (10/17668-6)
BORGES, NATALIA M.; DO VALE ELIAS, MARCELA; FOOK-ALVES, VERUSKA L.; ANDRADE, TATHIANA A.; DE CONTI, MARINA LOURENCO; MACEDO, MARIANA PETACCIA; BEGNAMI, MARIA DIRLEI; CAMPOS, ANTONIO HUGO J. F. M.; ETTO, LEINA YUKARI; BORTOLUZZO, ADRIANA BRUSCATO; et al. Angiomirs expression profiling in diffuse large B-Cell lymphoma. ONCOTARGET, v. 7, n. 4, p. 4806-4816, JAN 26 2016. Web of Science Citations: 8. (10/17668-6)
BRAGA, WALTER M. T.; DA SILVA, BRUNA R.; ALVES, VERUSKA L. F.; BORTOLUZO, ADRIANA B.; ATANACKOVIC, DJORDJE; COLLEONI, GISELE W. B.. Is there any relationship between gene expression of tumor antigens and CD4(+) T cells in multiple myeloma?. Immunotherapy, v. 6, n. 5, p. 569-575, MAY 2014. Web of Science Citations: 1. (10/17668-6)
PEREIRA EUGENIO, ANGELA ISABEL; FOOK-ALVES, VERUSKA LIA; DE OLIVEIRA, MARIANA BLEKER; FERNANDO, RODRIGO CARLINI; ZANATTA, DANIELA B.; STRAUSS, BRYAN ERIC; REGIS SILVA, MARIA REGINA; PORCIONATTO, MARIMELIA APARECIDA; BRAGA COLLEONI, GISELE WALLY. Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma. ONCOTARGET, v. 8, n. 70, p. 114698-114709, DEC 29 2017. Web of Science Citations: 4. (10/17668-6)
DE OLIVEIRA, MARIANA B.; SANSON, LUIZ F. G.; EUGENIO, ANGELA I. P.; BARBOSA-DANTAS, REBECCA S. S.; COLLEONI, GISELE W. B.. Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines. CURRENT MOLECULAR MEDICINE, v. 19, n. 2, p. 112-119, 2019. Web of Science Citations: 0. (10/17668-6)
FOOK-ALVES, VERUSKA L.; DE OLIVEIRA, MARIANA BLEKER; ZANATTA, DANIELA B.; STRAUSS, BRYAN E.; COLLEONI, GISELE W. B.. TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell line. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, v. 1862, n. 6, p. 1105-1110, JUN 2016. Web of Science Citations: 5. (10/17668-6)
POLES, WAGNER A.; NISHI, ERIKA E.; DE OLIVEIRA, MARIANA B.; EUGENIO, ANGELA I. P.; DE ANDRADE, TATHIANA A.; CAMPOS, ANTONIO HUGO F. M.; DE CAMPOS, JR., RUY R.; VASSALLO, JOSE; ALVES, ANTONIO C.; NETO, CRISTOVAM SCAPULATEMPO; et al. Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly. CANCER IMMUNOLOGY IMMUNOTHERAPY, v. 68, n. 2, p. 269-282, FEB 2019. Web of Science Citations: 2. (10/17668-6)
COTRIM GUERREIRO DA SILVA, ISMAEL DALE; DE CASTRO LEVATTI, ERICA VALADARES; PEDROSO, AMANDA PAULA; LOBO MARCHIONI, DIRCE MARIA; FERREIRA CARIOCA, ANTONIO AUGUSTO; BRAGA COLLEONI, GISELE WALLY. Biochemical phenotyping of multiple myeloma patients at diagnosis reveals a disorder of mitochondrial complexes I and II and a Hartnup-like disturbance as underlying conditions, also influencing different stages of the disease. SCIENTIFIC REPORTS, v. 10, n. 1, DEC 14 2020. Web of Science Citations: 0. (17/21801-2, 10/17668-6)
DE FARIA-MOSS, MARIANE; YAMAMOTO, MIHOKO; ARRAIS-RODRIGUES, CELSO; CRIADO, IGNACIO; GOMES, CAIO PEREZ; CHAUFFAILLE, MARIA DE LOURDES; GONCALVES, MATHEUS VESCOVI; KIMURA, ELIZA; KOULIERIS, EFSTATHIOS; BORGES, FABIO; et al. High frequency of chronic lymphocytic leukemia-like low-count monoclonal B-cell lymphocytosis in Japanese descendants living in Brazil. Haematologica, v. 105, n. 6, p. E298-E301, JUN 2020. Web of Science Citations: 0. (10/17668-6)
DE ANDRADE, TATHIANA AZEVEDO; EVANGELISTA, ADRIANE FEIJO; FROES CAMPOS, ANTONIO HUGO; POLES, WAGNER AUGUSTO; BORGES, NATALIA MORAIS; COUTINHO CAMILLO, CLAUDIA MALHEIROS; SOARES, FERNANDO AUGUSTO; VASSALLO, JOSE; PAES, ROBERTO PINTO; ZERBINI, MARIA CLAUDIA; et al. A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly. ONCOTARGET, v. 5, n. 23, p. 11813-11826, DEC 15 2014. Web of Science Citations: 22. (10/17668-6)